Shares of Athersys (NASDAQ:ATHX) jumped more than 18% today after the company announced that a collaboration partner has enrolled the first patient in a clinical trial in Japan. Healios is evaluating a product derived from MultiStem, the novel stem cell platform developed by Athersys, as a potential treatment for pneumonia-induced acute respiratory distress syndrome (ARDS).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,